Table 4.
Proportion of patients treated with preferred vs. non-preferred two drug class antihypertensive therapy by comorbidity
| Two drug class antihypertensive therapy | Comorbidityb | ||
|---|---|---|---|
| Post-MI | Diabetes | Uncomplicated | |
| n = 1,582 | n = 3,989 | n = 4,690 | |
| Preferreda | |||
| ACEI/ARB + DIUR | 188 (12) | 1,283 (32) | 1,839 (39) |
| ACEI/ARB + CCB | 124 (8) | 685 (17) | 733 (16) |
| ACEI/ARB + BB (post-MI) | 737 (47) | 781 (20) | 539 (11) |
| Non-preferred | |||
| BB + DIUR | 237 (15) | 429 (11) | 592 (13) |
| BB + dCCB | 104 (6) | 226 (6) | 229 (5) |
| CCB + DIUR | 65 (4) | 225 (5) | 446 (9) |
| Other | 105 (6) | 286 (7) | 224 (5) |
| Harmful | |||
| ACEI + ARB | 2 (0.1) | 36 (1) | 45 (1) |
| BB + ndCCB | 20 (1) | 38 (1) | 43 (1) |
Number of patients with percentage (%) shown in parentheses.
Abbreviations: MI, myocardial infarction; CKD, chronic kidney disease; UC, uncomplicated hypertension; IHD, ischemic heart disease; TIA, transient ischemic attack; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; BB, beta-blocker; DIUR, diuretic; CCB, calcium-channel blocker; dCCB, dihydropyridine calcium-channel blocker; ndCCB, non-dihydropyridine calcium-channel blocker.
aPreferred dual therapy for post-MI patients was defined as ACEI/ARB + BB. For patients with diabetes without MI, or uncomplicated hypertension, preferred dual therapy was defined as ACEI/ARB + CCB/diuretic. Uncomplicated hypertension was defined as lack of history of IHD, diabetes, CKD, stroke, or TIA.
bComorbidity groups are not mutually exclusive; comorbidity groups defined as all post-MI patients, diabetes patients without MI, uncomplicated hypertensive patients without history of IHD, diabetes, CKD, stroke, or TIA.